Values as of: 2024-11-17
COMMON STOCK | Health Information Services |
Last Closing
USD 16.9Change
0.00 (0.00)%Market Cap
USD 1.22BVolume
100.00Analyst Target
N/AVerdict
Verdict
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware. Address: 1521 Concord Pike, Wilmington, DE, United States, 19803
Company Website : https://www.phreesia.com
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| L0T:F | GE HEALTHCARE TECH.INC. |
N/A |
USD 37.60B |
| 2HE:F | Healthequity Inc |
N/A |
USD 6.90B |
| 4YC:F | M3 INC. |
N/A |
USD 5.81B |
| 6HL0:F | R1 RCM Inc |
N/A |
USD 5.59B |
| OC9:F | Omnicell Inc |
N/A |
USD 2.04B |
| 1XZ:F | Ping An Healthcare and Technol.. |
N/A |
USD 2.03B |
| 1KJ:F | 10X GENOMICS DL -00001 |
N/A |
USD 1.73B |
| 9EH:F | Evolent Health Inc |
N/A |
USD 1.67B |
| 6JM:F | JMDC INC. |
N/A |
USD 1.65B |
| 4LL:F | Teladoc Inc |
N/A |
USD 1.55B |
N/A
| Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -20.28% | 39% | F | 28% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -20.28% | 36% | F | 27% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 18.18% | 70% | C- | 63% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 18.18% | 62% | D | 59% | D- | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 3.01% | 73% | C | 51% | F | ||
| Dividend Return | 3.01% | 70% | C- | 45% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 9.13% | 97% | N/A | 91% | A- | ||
| Risk Adjusted Return | 32.92% | 79% | B- | 56% | F | ||
| Market Capitalization | 1.22B | 84% | B | 61% | D- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
